Combining PD-1/PD-L1 inhibitors (e.g., pembrolizumab, durvalumab, nivolumab) with osimertinib has drawn considerable attention as a strategy to overcome acquired resistance in EGFR-mutant NSCLC [312,313]. Here, CD274 is linked to non-small cell lung carcinoma.